Real‑world outcome of universal screening for Lynch syndrome in Japanese patients with colorectal cancer highlights the importance of targeting patients with young‑onset disease

Yamada,Atsushi; Yamada,Atsushi; Matsuoka,Yui; Matsuoka,Yui; Minamiguchi,Sachiko; Minamiguchi,Sachiko; Yamamoto,Yoshihiro; Yamamoto,Yoshihiro; Kondo,Tomohiro; Kondo,Tomohiro; Sunami,Tomohiko; Sunami,Tomohiko; Horimatsu,Takahiro; Horimatsu,Takahiro; Kawada,Kenji; Kawada,Kenji; Seno,Hiroshi; Seno,Hiroshi; Torishima,Masako; Torishima,Masako; Murakami,Hiromi; Murakami,Hiromi; Yamada,Takahiro; Yamada,Takahiro; Kosugi,Shinji; Kosugi,Shinji; Sugano,Kokichi; Sugano,Kokichi; Muto,Manabu; Muto,Manabu

doi:10.3892/mco.2021.2409

Real‑world outcome of universal screening for Lynch syndrome in Japanese patients with colorectal cancer highlights the importance of targeting patients with young‑onset disease

Authors:
- Atsushi Yamada
- Yui Matsuoka
- Sachiko Minamiguchi
- Yoshihiro Yamamoto
- Tomohiro Kondo
- Tomohiko Sunami
- Takahiro Horimatsu
- Kenji Kawada
- Hiroshi Seno
- Masako Torishima
- Hiromi Murakami
- Takahiro Yamada
- Shinji Kosugi
- Kokichi Sugano
- Manabu Muto
View Affiliations

Affiliations: Department of Clinical Oncology, Kyoto University Hospital, Kyoto City, Kyoto 606‑8507, Japan, Department of Diagnostic Pathology, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto 606‑8507, Japan, Department of Surgery, Kyoto University Hospital, Kyoto City, Kyoto 606‑8507, Japan, Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto 606‑8507, Japan, Clinical Genetics Unit, Kyoto University Hospital, Kyoto City, Kyoto 606‑8507, Japan, Oncogene Research Unit and Cancer Prevention Unit, Tochigi Cancer Center Research Institute, Utsunomiya, Tochigi 320‑0834, Japan
Published online on: October 1, 2021 https://doi.org/10.3892/mco.2021.2409
Article Number: 247

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite the recommendations of the latest guidelines, the practical efficacy of universal screening for identifying Lynch syndrome (LS) among patients with colorectal cancer (CRC) may be limited in the real world due to infrequent referrals and the difficulties of genetic testing. Thus, the present study aimed to retrospectively analyze the results of universal screening of patients with CRC at a referral hospital in Japan. Immunohistochemistry was performed for mismatch repair proteins [including DNA mismatch repair protein MSH6 (MSH6), mismatch repair endonuclease PMS2 (PMS2), DNA mismatch repair protein Msh2 (MSH2) and DNA mismatch repair protein Mlh1 (MLH1)] and BRAF V600E mutation. Tumors that showed the following were considered to indicate LS and patients with such tumors were designated as genetic testing candidates (GTCs): i) Loss of MSH6/MSH2; ii) loss of MSH6 alone; iii) loss of PMS2 alone; and iv) loss of PMS2/MLH1 with negative BRAF V600E. MLH1 methylation and BRAF V600E mutation were analyzed in deficient mismatch repair (dMMR) tumors retrospectively. The frequency of dMMR and GTCs in an independent cohort of patients with young‑onset CRC were also investigated. Universal screening revealed dMMR tumors, GTCs and LS probands in 7.3, 3.9 and 0.4%, respectively, of 463 patients with CRC. Although dMMR tumors were observed in both younger (<50 years) and older (≥60 years) patients, the GTCs were enriched in younger individuals. Evaluation of mismatch repair status in an independent cohort confirmed the high rate of GTCs in patients with young‑onset CRC. The low detection rate of LS demonstrated in this study questions the implementation of routine universal screening in regions with low prevalence of LS. Considering the enrichment of GTCs in young‑onset CRCs, age‑restricted strategies may be simple and efficient practical alternatives to universal screening in the real world.

View Figures

View References

1	Kastrinos F and Stoffel EM: History, genetics, and strategies for cancer prevention in Lynch syndrome. Clin Gastroenterol Hepatol. 12:715–727. 2014.PubMed/NCBI View Article : Google Scholar
2	Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, De La Chapelle A and Mecklin JP: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 118:829–834. 2000.PubMed/NCBI View Article : Google Scholar
3	Vasen HF, Watson P, Mecklin JP and Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 116:1453–1456. 1999.PubMed/NCBI View Article : Google Scholar
4	Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, et al: Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 96:261–268. 2004.PubMed/NCBI View Article : Google Scholar
5	Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, et al: Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 26:5783–5788. 2008.PubMed/NCBI View Article : Google Scholar
6	Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, et al: Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 308:1555–1565. 2012.PubMed/NCBI View Article : Google Scholar
7	Di Marco M, DAndrea E, Panic N, Baccolini V, Migliara G, Marzuillo C, De Vito C, Pastorino R, Boccia S and Villari P: Which Lynch syndrome screening programs could be implemented in the ‘Real World’? A systematic review of economic evaluations. Genet Med. 20:1131–1144. 2018.PubMed/NCBI View Article : Google Scholar
8	Mvundura M, Grosse SD, Hampel H and Palomaki GE: The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 12:93–104. 2010.PubMed/NCBI View Article : Google Scholar
9	Adar T, Rodgers LH, Shannon KM, Yoshida M, Ma T, Mattia A, Lauwers GY, Iafrate AJ, Hartford NM, Oliva E and Chung DC: Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. Cancer. 124:3145–3153. 2018.PubMed/NCBI View Article : Google Scholar
10	Dillon JL, Gonzalez JL, DeMars L, Bloch KJ and Tafe LJ: Universal screening for Lynch syndrome in endometrial cancers: Frequency of germline mutations and identification of patients with Lynch-like syndrome. Hum Pathol. 70:121–128. 2017.PubMed/NCBI View Article : Google Scholar
11	Egoavil C, Alenda C, Castillejo A, Paya A, Peiro G, Sánchez-Heras AB, Castillejo MI, Rojas E, Barberá VM, Cigüenza S, et al: Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS One. 8(e79737)2013.PubMed/NCBI View Article : Google Scholar
12	Ryan NAJ, Glaire MA, Blake D, Cabrera-Dandy M, Evans DG and Crosbie EJ: The proportion of endometrial cancers associated with Lynch syndrome: A systematic review of the literature and meta-analysis. Genet Med. 21:2167–2180. 2019.PubMed/NCBI View Article : Google Scholar
13	Gupta S, Provenzale D, Llor X, Halverson AL, Grady W, Chung DC, Haraldsdottir S, Markowitz AJ, Slavin TP Jr, Hampel H, et al: NCCN Guidelines Insights: Genetic/familial high-risk assessment: Colorectal, version 2.2019. J Natl Compr Cancer Netw. 17:1032–1041. 2019.PubMed/NCBI View Article : Google Scholar
14	Crosbie EJ, Ryan NAJ, Arends MJ, Bosse T, Burn J, Cornes JM, Crawford R, Eccles D, Frayling IM, Ghaem-Maghami S, et al: The manchester international consensus group recommendations for the management of gynecological cancers in Lynch syndrome. Genet Med. 21:2390–2400. 2019.PubMed/NCBI View Article : Google Scholar
15	Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, et al: Guidelines on genetic evaluation and management of Lynch syndrome: A consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol. 109:1159–1179. 2014.PubMed/NCBI View Article : Google Scholar
16	Rubenstein JH, Enns R, Heidelbaugh J and Barkun A: Clinical Guidelines Committee. American gastroenterological association institute guideline on the diagnosis and management of lynch syndrome. Gastroenterology. 149:777–782. 2015.PubMed/NCBI View Article : Google Scholar
17	Vangala DB, Cauchin E, Balmaña J, Wyrwicz L, van Cutsem E, Güller U, Castells A, Carneiro F, Hammel P, Ducreux M, et al: Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. Eur J Cancer. 104:91–103. 2018.PubMed/NCBI View Article : Google Scholar
18	Brennan B, Hemmings CT, Clark I, Yip D, Fadia M and Taupin DR: Universal molecular screening does not effectively detect Lynch syndrome in clinical practice. Therap Adv Gastroenterol. 10:361–371. 2017.PubMed/NCBI View Article : Google Scholar
19	Chika N, Eguchi H, Kumamoto K, Suzuki O, Ishibashi K, Tachikawa T, Akagi K, Tamaru JI, Okazaki Y and Ishida H: Prevalence of Lynch syndrome and Lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population. Jpn J Clin Oncol. 47:108–117. 2017.PubMed/NCBI View Article : Google Scholar
20	Jiang W, Cai MY, Li SY, Bei JX, Wang F, Hampel H, Ling YH, Frayling IM, Sinicrope FA, Rodriguez-Bigas MA, et al: Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. Int J Cancer. 144:2161–2168. 2019.PubMed/NCBI View Article : Google Scholar
21	Li D, Hoodfar E, Jiang SF, Udaltsova N, Pham NP, Jodesty Y, Armstrong MA, Hung YY, Baker RJ, Postlethwaite D, et al: Comparison of universal versus age-restricted screening of colorectal tumors for lynch syndrome using mismatch repair immunohistochemistry: A cohort study. Ann Intern Med. 171:19–26. 2019.PubMed/NCBI View Article : Google Scholar
22	Pabinger S, Ernst K, Pulverer W, Kallmeyer R, Valdes AM, Metrustry S, Katic D, Nuzzo A, Kriegner A, Vierlinger K and Weinhaeusel A: Analysis and visualization tool for targeted amplicon bisulfite sequencing on ion torrent sequencers. PLoS One. 11(e0160227)2016.PubMed/NCBI View Article : Google Scholar
23	Crockett SD and Nagtegaal ID: Terminology, molecular features, epidemiology, and management of serrated colorectal neoplasia. Gastroenterology. 157:949–966.e4. 2019.PubMed/NCBI View Article : Google Scholar
24	Shia J, Tang LH, Vakiani E, Guillem JG, Stadler ZK, Soslow RA, Katabi N, Weiser MR, Paty PB, Temple LK, et al: Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: A 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 33:1639–1645. 2009.PubMed/NCBI View Article : Google Scholar
25	Pearlman R, Markow M, Knight D, Chen W, Arnold CA, Pritchard CC, Hampel H and Frankel WL: Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency. Mod Pathol. 31:1891–1900. 2018.PubMed/NCBI View Article : Google Scholar
26	Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, von Knebel Doeberitz M and Kloor M: BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer. 133:1624–1630. 2013.PubMed/NCBI View Article : Google Scholar
27	Toon CW, Walsh MD, Chou A, Capper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters RJ, Clendenning M, et al: BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol. 37:1592–1602. 2013.PubMed/NCBI View Article : Google Scholar
28	Adar T, Rodgers LH, Shannon KM, Yoshida M, Ma T, Mattia A, Lauwers GY, Iafrate AJ and Chung DC: A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome. Mod Pathol. 30:440–447. 2017.PubMed/NCBI View Article : Google Scholar
29	Newton K, Jorgensen NM, Wallace AJ, Buchanan DD, Lalloo F, McMahon RF, Hill J and Evans DG: Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). J Med Genet. 51:789–796. 2014.PubMed/NCBI View Article : Google Scholar
30	Pérez-Carbonell L, Alenda C, Payá A, Castillejo A, Barberá VM, Guillén C, Rojas E, Acame N, Gutiérrez-Aviñó FJ, Castells A, et al: Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. J Mol Diagn. 12:498–504. 2010.PubMed/NCBI View Article : Google Scholar